

Media Release

Canexis Pharma AG receives Swissmedic Approval to Manufacture Medical Cannabis Products

Schlattingen, April 18, 2024 - Canexis Pharma AG ("Canexis"), an emerging Swiss company in the field of pharmaceutical cannabis products, has received manufacturing and narcotics licensing for cannabis pharmaceuticals from Swissmedic. These licenses mark a significant milestone for Canexis, enabling the company to produce high-quality medicinal active ingredients based on CBD and THC for both the Swiss and international markets.

After four years of intensive preparation and development, production is now underway at the specially designed facility in Schlattingen, Canton of Thurgau. The state-of-the-art building was planned around the production process, designed from the outset to meet GMP standards, and completed in 2022. It houses the most advanced technology in cleanrooms over an area of more than 2,000 square meters, meeting the highest quality requirements. Six months after the facilities began operations, a successful initial inspection confirmed compliance with all required standards, leading to the issuance of the relevant approvals by Swissmedic in April 2024. Thus, Canexis Pharma AG has met all the requirements for market entry and will supply pharmacies and other pharmaceutical companies with active ingredients throughout 2024.

Innovative Processes and Global Cooperations

Canexis has made a name for itself through comprehensive expertise in cannabis extraction and a very high level of GMP (Good Manufacturing Practice). Accordingly, all processes and facilities are specifically designed for the extraction and further processing of cannabis. By optimizing equipment from European market leaders for its own production and exchanging knowledge with leading U.S. cannabis companies, Canexis has integrated extensive experience into the manufacturing process, leading to a significant competitive advantage in product quality, efficiency, and product portfolio.

"In just four years, our team has built a pharmaceutical company from scratch despite several global challenges. We are now looking forward to shifting our focus from building up to taking a new perspective and actively contributing to the development of the cannabis pharmaceutical market," said Sebastian Zeller, CEO of Canexis.

Currently, the market for medical cannabis is dominated by individually tailored prescription medicines. Canexis plans to enrich this market with a range of finished pharmaceutical products based on pure active ingredients directly extracted from the plant. Canexis production facility can process up to 1,000 kg of cannabis daily, resulting in 100 kg of pure active ingredients per day. This capacity enables Canexis to meet the daily needs of one to four million patients.



Photo: The three-story production facility of Canexis in Schlattingen, Canton of Thurgau. The equipment park was commissioned in 2023 with the latest technology in the cleanrooms.

About Canexis Pharma AG

Founded in 2020, Canexis Pharma AG specializes in the research and development of pharmaceutical cannabis products. Its own production facility in Schlattingen, Canton of Thurgau, meets the highest quality and safety standards. The manufacturing and narcotics licenses from Swissmedic allow Canexis to create innovative and safe pharmaceutical products, thereby enhancing the quality of life for patients.

Canexis Pharma AG

Hauptstrasse 25
8255 Schlattingen
Schweiz
+41 52 657 47 01
www.canexis.ch

Media Contact

Sebastian Zeller
CEO
s.zeller@canexis.ch